Molecular characterization of rifabutin-resistance in refractory Helicobacter pylori infection in Taiwan

Int J Infect Dis. 2024 Jan:138:25-28. doi: 10.1016/j.ijid.2023.11.001. Epub 2023 Nov 11.

Abstract

Objectives: To explore the molecular characteristics of rpoB, encoding β-subunit of DNA-directed RNA polymerase, and unravel the link to rifabutin-resistance in patients with refractory Helicobacter pylori infection.

Methods: From January 2018-March 2021, a total of 1590 patients were screened for eligibility to participate in the study. Patients with refractory H. pylori infection were confirmed by using the (13C)-urea breath assay. All enrolled patients underwent esophagogastroduodenoscopy, and biopsies were taken for H. pylori culture and antibacterial susceptibility testing. Sequence analysis of rpoB was conducted for all rifabutin-resistant isolates.

Results: In total, 70 patients were diagnosed with refractory H. pylori infection, and 39 isolates were successfully cultured. Amongst, 10 isolates were identified as rifabutin-resistance and nine isolates exhibited at least one amino acid substitution in RpoB. Isolates with a minimal inhibitory concentration >32 mg/l displayed a higher number of mutational changes in RpoB than the others. Additionally, more amino acid substitutions in RpoB correlated with developing a higher minimal inhibitory concentration for H. pylori rifabutin-resistance.

Conclusion: Our findings highlight the relationship between rifabutin-resistance in refractory H. pylori infection and specific mutations in RpoB, which will aid the clinical selection of appropriate antibacterial agents with better therapeutic effects.

Keywords: Helicobacter pylori; Mutation; Refractory infection; Rifabutin-resistance; RpoB.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Helicobacter Infections* / drug therapy
  • Helicobacter Infections* / microbiology
  • Helicobacter pylori*
  • Humans
  • Microbial Sensitivity Tests
  • Rifabutin / pharmacology
  • Rifabutin / therapeutic use
  • Rifampin / therapeutic use
  • Taiwan / epidemiology

Substances

  • Rifabutin
  • Rifampin
  • Anti-Bacterial Agents